Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation
Carregando...
Citações na Scopus
54
Tipo de produção
article
Data de publicação
2019
Editora
ELSEVIER SCIENCE BV
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
SRIGLEY, John R.
DELAHUNT, Brett
SAMARATUNGA, Hemamali
BILLIS, Athanase
CHENG, Liang
CLOUSTON, David
EVANS, Andrew
FURUSATO, Bungo
KENCH, James
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PATHOLOGY, v.51, n.5, p.463-473, 2019
Resumo
The Gleason Grading system has been used for over 50 years to prognosticate and guide the treatment for patients with prostate cancer. At consensus conferences in 2005 and 2014 under the guidance of the International Society of Urological Pathology (ISUP), the system has undergone major modifications to reflect modern diagnostic and therapeutic practices. The 2014 consensus conference yielded recommendations regarding cribriform, mucinous, glomeruloid and intraductal patterns, the most significant of which was the removal of any cribriform pattern from Gleason grade 3. Furthermore, a Gleason score grouping system was endorsed which consisted of five grades where Gleason score 6 (3+3) was classified as grade 1 which better reflected the mostly indolent behaviour of these tumours. Another issue discussed at the meeting and subsequently endorsed was that in Gleason score 7 cases, the percentage pattern 4 should be recorded. This is especially important in situations where modern active surveillance protocols expand to include men with low volume pattern 4. While major progress was made at the conference, several issues were either not resolved or not discussed at all. Most of these items relate to details of assignment of Gleason score and ISUP grade in specific specimen types and grading scenarios. This detailed review looks at the 2014 ISUP conference results and subsequent literature from an international perspective and proposes several recommendations. The specific issues addressed are percentage pattern 4 in Gleason score 7 tumours, percentage patterns 4 and 5 or 4/5 in Gleason score 8-10 disease, minor (<= 5%) high grade patterns when either 2 or 3 patterns are present, level of reporting (core, specimen, case), dealing with grade diversity among site (highest and composite scores) and reporting scores in radical prostatectomy specimens with multifocal disease. It is recognised that for many of these issues, a strong evidence base does not exist, and further research studies are required. The proposed recommendations mostly reflect consolidated expert opinion and they are classified as established if there was prior agreement by consensus and provisional if there was no previous agreement or if the item was not discussed at prior consensus conferences. For some items there are reporting options that reflect the local requirements and diverse practice models of the international urological pathology community. The proposed recommendations provide a framework for discussion at future consensus meetings.
Palavras-chave
Prostate adenocarcinoma, grading, ISUP grade, Gleason, International Society of Urological Pathology
Referências
- Amin MB, 2014, ARCH PATHOL LAB MED, V138, P1387, DOI 10.5858/arpa.2014-0219-SA
- Amin MB, 2017, AJCC CANC STAGING MA
- Arora R, 2004, CANCER-AM CANCER SOC, V100, P2362, DOI 10.1002/cncr.20243
- Baras AS, 2017, HUM PATHOL, V63, P27, DOI 10.1016/j.humpath.2016.12.008
- Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86
- Berney DM, 2014, HISTOPATHOLOGY, V64, P405, DOI 10.1111/his.12284
- Chan TY, 2000, UROLOGY, V56, P823, DOI 10.1016/S0090-4295(00)00753-6
- Danneman D, 2015, BJU INT, V115, P248, DOI 10.1111/bju.12671
- Delahunt B, 2015, PATHOLOGY, V47, P520, DOI 10.1097/PAT.0000000000000318
- Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb
- Delahunt B, 2012, HISTOPATHOLOGY, V60, P75, DOI 10.1111/j.1365-2559.2011.04003.x
- Descazeaud A, 2005, EUR UROL, V48, P911, DOI 10.1016/j.eururo.2005.07.011
- Egevad L, 2002, J UROLOGY, V168, P509, DOI 10.1016/S0022-5347(05)64669-1
- Egevad L, 2017, PROSTATE CORE NEEDLE
- Egevad L, 2017, PROSTATE CANC RADICA
- Egevad L, 2019, PATHOLOGY, V51, P11, DOI 10.1016/j.pathol.2018.10.003
- Egevad L, 2016, AM J SURG PATHOL, V40, P858, DOI 10.1097/PAS.0000000000000642
- Egevad L, 2011, HISTOPATHOLOGY, V59, P1011, DOI 10.1111/j.1365-2559.2011.03925.x
- Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1
- Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001
- Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820
- Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530
- Glaessgen A, 2004, J UROLOGY, V171, P664, DOI 10.1097/01.ju.0000108198.98598.00
- Glaessgen A, 2002, J UROLOGY, V168, P2006, DOI 10.1097/01.ju.0000034255.95952.df
- Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171
- GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125
- Grogan J, 2017, BJU INT, V120, P651, DOI 10.1111/bju.13857
- Haffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354
- Huang CC, 2014, VIRCHOWS ARCH, V464, P589, DOI 10.1007/s00428-014-1557-y
- Isbarn H, 2009, EUR UROL, V55, P394, DOI 10.1016/j.eururo.2008.08.015
- Jang WS, 2017, PROSTATE CANCER P D, V20, P93, DOI 10.1038/pcan.2016.55
- Kato M, 2019, MODERN PATHOL, V32, P122, DOI 10.1038/s41379-018-0121-8
- Kench JG, 2019, VIRCHOWS ARCH
- Kunju LP, 2009, HUM PATHOL, V40, P558, DOI 10.1016/j.humpath.2008.07.020
- Lindberg J, 2015, EUR UROL, V67, P819, DOI 10.1016/j.eururo.2014.09.006
- Lindberg J, 2013, EUR UROL, V63, P347, DOI 10.1016/j.eururo.2012.03.050
- Loeb S, 2016, EUR UROL, V69, P1135, DOI 10.1016/j.eururo.2015.11.036
- MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X
- Moch H, 2016, WHO CLASSIFICATION T
- Mohler JL, 2019, J NATL COMPR CANC NE, V17, P479, DOI 10.6004/jnccn.2019.0023
- Morash C, 2015, CUAJ-CAN UROL ASSOC, V9, P171, DOI 10.5489/cuaj.2806
- Pan CC, 2000, AM J SURG PATHOL, V24, P563, DOI 10.1097/00000478-200004000-00011
- Paner GP, 2017, PROTOCOL EXAMINATION
- Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445
- Poulos CK, 2005, MODERN PATHOL, V18, P228, DOI 10.1038/modpathol.3800302
- Qi R, 2017, CAN J UROL, V24, P8982
- Sadimin ET, 2016, AM J SURG PATHOL, V40, P1686, DOI 10.1097/PAS.0000000000000714
- Sakr WA, 2000, UROLOGY, V56, P730, DOI 10.1016/S0090-4295(00)00791-3
- Samaratunga H, 2015, PATHOLOGY, V47, P515, DOI 10.1097/PAT.0000000000000315
- Samaratunga H, 2011, MODERN PATHOL, V24, P6, DOI 10.1038/modpathol.2010.178
- Sauter G, 2016, EUR UROL, V69, P592, DOI 10.1016/j.eururo.2015.10.029
- Shariat SF, 2008, CANCER-AM CANCER SOC, V113, P3075, DOI 10.1002/cncr.23908
- Srigley JR, 2014, PATHOLOGY, V46, P579, DOI 10.1097/PAT.0000000000000183
- Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1
- Srigley JR, 2009, ARCH PATHOL LAB MED, V133, P1568, DOI 10.1043/1543-2165-133.10.1568
- Srigley JR, 2000, ARCH PATHOL LAB MED, V124, P1034
- Stamey TA, 2000, J UROLOGY, V163, P1155, DOI 10.1016/S0022-5347(05)67713-0
- Stamey TA, 1999, JAMA-J AM MED ASSOC, V281, P1395, DOI 10.1001/jama.281.15.1395
- Stephenson AJ, 2006, JNCI-J NATL CANCER I, V98, P715, DOI 10.1093/jnci/djj190
- Tolonen TT, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-21
- van der Kwast TH, 2011, MODERN PATHOL, V24, P16, DOI 10.1038/modpathol.2010.156
- van Oort IM, 2005, EUR UROL, V48, P572, DOI 10.1016/j.eururo.2005.06.003